CAS NO: | 263707-16-0 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | ESI-09 is a novel noncyclic nucleotideEPACantagonist withIC50values of 3.2 and 1.4 μM for EPAC1 and EPAC2, respectively. | ||||||||||||||||
IC50& Target | IC50: 3.2 μM (EPAC1), 1.4 μM (EPAC2)[1] | ||||||||||||||||
体外研究 (In Vitro) | While cAMP competes with 8-NBD-cAMP binding with an IC50of 39 μM, ESI-09 shows an increased potency with an apparent IC50of 10 μM. ESI-09 inhibis cAMP-mediated EPAC2 and EPAC1 GEF activity with an IC50of 1.4 and 3.2μM, respectively. ESI-09 could fit well into the functional cAMP-binding pocket of EPAC1, establishing favorable hydrophobic and hydrogen bonding interactions with the protein’s active-site residues. ESI-09 inhibits 007-AM-stimulated Akt phosphorylation at T308 and S473 in a dose-dependent manner. ESI-09 inhibits pancreatic cancer cells AsPC-1 and PANC-1 migration. ESI-09 inhibits EPAC1-mediated adhesion of PDA cells on collagen I[1]. Exposure to ESI-09 significantly reduces intracellular and total bacterial counts in HUVECs at 30 min postinfection with 10 multiplicities of infection (MOI) ofR. australiscompared with similarly infected controls[2]. | ||||||||||||||||
体内研究 (In Vivo) | Treatment with ESI-09 dramatically protects WT mice againstR. australisinfection with much milder disease manifestations and significantly improves survival[2]. | ||||||||||||||||
分子量 | 330.77 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C16H15ClN4O2 | ||||||||||||||||
CAS 号 | 263707-16-0 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : ≥ 47 mg/mL(142.09 mM) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|